A typical hemolytic uremic syndrome (aHUS) presents similarly to thrombotic thrombocytopenic purpura (TTP) and other causes or conditions with thrombotic microangiopathy (TMA), such as disseminated intravascular coagulation or sepsis. Similarity in clinical presentation may hinder diagnosis and optimal treatment selection in the urgent setting in the ICU. However, there is currently no consensus on the diagnosis or treatment of aHUS for ICU specialists. This review aims to summarize available data on the diagnosis and treatment strategies of aHUS in the ICU to enhance the understanding of aHUS diagnosis and outcomes in patients managed in the ICU. To this end, a review of the recent literature (January 2009-March 2016) was performed to select the most relevant articles for ICU physicians. Based on the paucity of adult aHUS cases overall and within the ICU, no specific recommendations could be formally graded for the critical care setting.
Thrombotic microangiopathies (TMAs) are a group of disorders characterized by thrombocytopenia, microangiopathic hemolytic anemia, and organ dysfunction, in which ischemic organ injury can occur to the brain, kidneys, heart, pancreas, liver, lungs, eyes, and skin. Conditions occurring with TMAs include hemolytic uremic syndromes (HUSs) and thrombotic thrombocytopenic purpura (TTP), and a number of differential diagnoses that must also be excluded (Fig 1) . 1 These conditions have a similar clinical presentation of consumptive thrombocytopenia, mechanical hemolysis, and organ failure, but with distinct causes, and are typically associated with thickening and inflammation of arterioles and capillaries, detachment and swelling of endothelial cells, subendothelial widening, accumulation of proteins and cellular debris, or platelet thrombi that obstruct the vascular lumen.
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Herein, we will focus on one of these conditions, atypical hemolytic uremic syndrome (aHUS). aHUS is a rare but life-threatening condition that affects both children and adults. It accounts for approximately 10% of cases of HUS in children, but most HUS cases in adults. 3 The annual incidence of aHUS is thought to be around 1 to 2 per million in adults 4 ; however, epidemiologic data are limited. 5 aHUS is distinct from typical, or diarrheaassociated, HUS, now commonly called Shiga toxinassociated hemolytic uremic syndrome (STEC-HUS), which is typically caused by Shiga toxin because of bacterial infection and often associated with bloody diarrhea. In most cases, aHUS is caused by the uncontrolled activation of the complement system, which leads to platelet, leucocyte, and endothelial cell activation and TMA, 1, [6] [7] [8] ultimately causing thrombosis and organ dysfunction. 8, 9 Accordingly, it may be unmasked by conditions with enhanced complement activation, such as systemic lupus erythematosus, pregnancy, malignant hypertension, and hematopoietic stem cell transplantation.
Genetic abnormalities have been found in approximately 50% to 70% of patients with aHUS, 4, 10 and a wide variety of mutations are associated with the condition. 
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Although gene mutations increase the risk of aHUS, they may not be sufficient to cause overt symptoms without additional environmental triggers. These include infections, pregnancy, certain medications, malignancy, sepsis, bone marrow transplantation, and connective tissue disorders. 2, 9, 11 Consequently, genetic testing is currently not useful for the acute diagnosis of aHUS (eg, in the ICU setting), but it can provide diagnostic confirmation, prognostic value, and information on long-term treatment. Furthermore, because of the severe nature of the condition, the time delay in obtaining genetic results is not consistent with the need for rapid initiation of therapy. In the absence of any fast, specific diagnostic tests for aHUS, the condition can only be diagnosed after exclusion of TTP 12 and related TMAs.
Previously, aHUS and TTP have been managed in the same way because the conditions are difficult to differentiate and only one treatment option, plasma therapy (plasma infusion or plasma exchange), was available. 1, 4 The benefits of plasma exchange, although not evaluated in prospective studies, include the removal of pathologic substances from the blood and the replacement of deficient plasma components. 13 However, although plasma therapy has improved outcomes considerably in TTP, reducing the mortality rate from 90% to 10% to 20%, 14 > 50% of patients with aHUS proceed to end-stage renal disease or death despite plasma therapy. 8, 12 Consequently, specific, urgent, and interdisciplinary management is paramount in the treatment of patients with aHUS because of both the severity of the illness and the potential development of irreversible complications of organ involvement. 1 Eculizumab, approved in 2011, is the first treatment for aHUS with proven efficacy and safety in prospective clinical trials. 6 This monoclonal antibody targets the complement system by blocking the cleavage of C5, avoiding the production of cleavage products C5a and C5b
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; evidence suggests that early initiation can improve renal and nonrenal recovery. 16, 17 In many cases, the ICU is the only clinical environment in which such specialized urgent care can be effectively provided at any time. Based on our experience, physicians in the ICU see an average of three patients with TMA per year, many of whom are not diagnosed at the time of admission. Although treatment guidelines for aHUS are available for nephrology, 14, [18] [19] [20] there is currently no consensus on the diagnosis or treatment of aHUS for ICU specialists. This review aims to summarize available data on the diagnosis and treatment of aHUS in the ICU with the goal of enhancing the understanding of aHUS diagnosis and outcomes in patients managed in the ICU.
Research Design and Methods
The need for this article was identified by a multidisciplinary multinational expert panel of 11 members (nine intensive care physicians and two hematologists) who met in September 2015 to define unmet needs and skill priorities for ICU clinicians managing critically ill patients with aHUS and to evaluate existing recommendations outside critical care. A literature search was conducted in the National Library of Medicine database (PubMed) looking for articles published between January 2009 and March 2016, using the following search terms: "atypical haemolytic uraemic syndrome" or "atypical hemolytic uremic syndrome" or "diarrhoea negative haemolytic uraemic syndrome" or "diarrhea negative hemolytic uremic syndrome" or "aHUS" or "D-HUS," with search filters of "humans" and "English language." Additional relevant articles were also included from Internet searches using the same search terms. Articles were reviewed manually for relevance by the authors; studies concerning both transplant and native kidney patients with aHUS were permitted in this study, as were systematic literature reviews and specialist review articles. In total, 539 articles were identified, of which 56 were considered relevant (included diagnosis and/or treatment of adult patients with aHUS).
Diagnosis of Patients With aHUS
Diagnosis of aHUS typically commences with the broad diagnosis of TMA (Fig 2, chestjournal.org adverse drug effect; however, identification of one of these modulating factors does not preclude development of aHUS in individuals with a genetic predisposition.
Additionally, an HIV test and a pregnancy test in women of child-bearing age should be performed to account for these potential triggers. Somewhat reduced ADAMTS13 activity levels (> 10% of normal) may also occur in aHUS, but such levels are sufficient to exclude TTP. Although results from the ADAMTS13 assay are typically available within a few hours when the assay is established in the local laboratory, they may take some additional days when the sample has to be shipped, meaning that treatment decisions may need to be made prior to receiving the results of the test. If ADAMTS13 tests are not available within a few hours, a diagnostic algorithm developed by Coppo et al, 34 in which TTP is suggested by low platelet count (< 30 Â 10 9 /L), mildly elevated serum creatinine (# 200 mmol/L), and detectable antinuclear antibodies, could help form an initial differential diagnosis. In the interim, until TTP has been excluded, patients should receive plasma exchange.
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Organ Involvement: The presence of associated organ involvement may be included within the diagnostic workup to provide evidence for differentiation of aHUS from TTP, but it is not conclusive. Renal impairment is the most common complication in aHUS (Fig 3) , but renal function may be preserved in up to 20% of cases. Acute kidney injury may be seen in TTP, but it is typically reversible with therapy. 35 The need for renal support, such as hemodialysis, is not a common feature of TTP, but it can be seen in progressive disease with multiorgan involvement.
Neurologic signs (eg, confusion, focal cerebral abnormalities, seizures) and cardiovascular signs (eg, cardiomyopathy, myocardial infarction, myocarditis, heart failure) occur in 10% to 48% and 10% of aHUS cases, respectively 9 ; however, these signs tend to be more frequent in TTP.
14,36 Tsai 37 reported that complications of abnormal vascular permeability (including brain edema, pleural or pericardial effusions, pulmonary edema from oliguria or cardiac insufficiency, and ascites) may be used to differentiate TTP from aHUS because they are thought to occur rarely in TTP without comorbidity. aHUS is also occasionally associated with large artery obstruction. 38 Arterial hypertension may be present, whereas pulmonary involvement is frequent in untreated aHUS but rarely associated with other TMAs. Genetic Testing: Genetic abnormalities in the complement system proteins have been documented, 41 and assessment of these mutations may be used to confirm a diagnosis. Mutations in complement factor H account for approximately 25% of aHUS cases, membrane cofactor protein for approximately 10%, complement factor I for 5% to 10%, and thrombomodulin for up to 5% of cases 42 ; however, no known mutations are identified in 30% to 50% of patients. 4, 10 Other genetic variants include gain-of-function mutations in the genes coding for complement factor B and C3, and anticomplement factor H antibodies associated with homozygous complement factor H-related 1-3 deletion. 4, 8 The parameters associated with clinical aHUS onset are yet to be wholly elucidated. The current hypothesis is a two-hit model: (1) preexisting genetic susceptibility factors that are capable of stimulating endothelial cell activation/damage and/or platelet aggregation; and (2) modulating factors, encompassing a variety of conditions that can be infectious, inflammatory, or related to pregnancy, drugs, or stress and are linked epidemiologically to both TTP and aHUS. 27 Mutations confer a genetic predisposition; therefore, although a positive result is compatible with the diagnosis, a negative chestjournal.org result does not necessarily exclude aHUS. Additionally, the results from such tests may take weeks, which is not compatible with the urgent care setting of the ICU, where rapid treatment decisions and administration of urgent therapy are necessities.
Distinguishing aHUS From STEC-HUS and Pneumococcal HUS
Culture-based assays (serology or polymerase chain reaction) for Shiga toxin-producing Escherichia coli (STEC), using a stool or rectal swab, in patients with diarrhea can diagnose STEC-HUS and clearly differentiate it from aHUS. Although E coli is not the only source of Shiga toxin, STEC-HUS, previously referred to as typical HUS or diarrhea-positive HUS, is the most commonly used terminology today and is used here to refer to this subset of HUS. The presence of diarrhea alone has been used in the past to differentiate between the conditions; however, this cannot be relied on because up to one-third of aHUS cases also involve diarrhea; therefore, so the presence of Shiga toxin must be analyzed in patients with diarrhea. 27 Pneumococcal HUS is linked to the evidence of invasive pneumococcal infection. Bacterial culture from sterile bodily fluids is required for confirmation of pneumococcal infection, and pneumococcal HUS is-in contrast with aHUS and TTP-often associated with a positive Coombs test. clinical characteristics of 516 patients with aHUS were recently published. 44 A review of the available case studies relevant to the ICU setting revealed that the initial diagnostic workup was similar for all patients, regardless of the presenting symptoms. It is notable that a variety of approaches were taken for progression beyond the TMA diagnosis, with most patients receiving initial plasma exchange while undergoing further investigations, including ADAMTS13 activity, Shiga toxin testing, kidney biopsy if feasible in critically ill patients, and genetic screening. Together, information from these case studies can inform an appropriate workup relevant to patients presenting with aHUS symptoms within the ICU. A summary of the key considerations for the differential diagnosis of aHUS in the ICU setting is presented in Table 2 .
Treatment of Patients With aHUS in the ICU
Knowing the standard of care for patients with aHUS, based on available guidelines and expert suggestions on best practice in the treatment of critically ill patients with aHUS, is a skill we consider necessary within the ICU. No published guidelines or recommendations focus on the management of patients in the ICU; however, there are no differences in treatment requirements between settings, and published treatment guidelines from other clinical settings apply.
Immediate ICU Management
The critical nature of acute TMA means that a high proportion of patients may be admitted to the ICU at presentation. Because of the severity of the progression of aHUS and other TMAs, a suspected diagnosis should be treated as a medical emergency, and initial supportive measures should be introduced with urgency. The British Committee for Standards in Haematology guidelines 14 suggest that appropriate treatment should be initiated within 4 to 8 h from diagnosis because delays are associated with increased morbidity and mortality.
Although plasma exchange has greatly improved the survival of patients with TTP, 12 it is not considered the most effective therapy for aHUS because most patients will die or require long-term renal replacement therapy despite this treatment. 4, 12, 40 However, because of the difficulty in differentiating between aHUS and TTP, initiation of plasma exchange is often necessary while laboratory results are being determined. 45 Exceptions include patients with metastatic cancer with bone marrow involvement for which plasma exchange would not improve the situation. Plasma exchange requires careful monitoring of organ function, platelet counts, and the presence of infections, which can arise from central venous lines and other sources related to medical interventions. Platelet concentrates should be avoided during initial therapy because they may aggravate platelet aggregation. 22 
Specific Management of aHUS
Once ADAMTS13 is proven detectable (> 10% activity), the probability of a diagnosis of aHUS is high, and more specific therapy can be applied. This can be confirmed with a negative test for STEC, once laboratory results have been received. Treatment options for aHUS were limited to plasma exchange, dialysis for renal failure, and kidney transplantation until 2011, when eculizumab, a recombinant, humanized, monoclonal antibody was approved for use in patients with aHUS. 12, 45 Eculizumab selectively targets and inhibits the terminal complement protein C5, thereby inhibiting the terminal complement activation. 46 Eculizumab has been demonstrated to be effective and well tolerated in four prospective phase II trials in patients with aHUS. [46] [47] [48] [49] These trials were however not carried out in the critical care setting. In these trials, terminal complement inhibition with eculizumab was associated with inhibition of further TMA progression, increased platelet count, and significant improvement in renal function, including discontinuation of dialysis in 5. If TMA persists on specific treatment of associated condition (Fig 1) , differential diagnosis for aHUS should be considered.
See Table 1 legend for expansion of abbreviations.
chestjournal.org 80% of patients on dialysis at initiation of treatment and prevention of recurrence after transplantation. 6 Based on these results, eculizumab was included in a 2015 update to the clinical guidelines 1 and in an international consensus for the treatment of aHUS in children in 2016. 19 In addition, a number of reviews on the management of patients with aHUS recommend the use of eculizumab. 14, 20, 21, 31, 45, 50, 51 However, eculizumab is contraindicated in patients with unresolved neisserial infection (eg, Neisseria meningitidis) and in unvaccinated individuals because of the role of terminal complement in the prevention of neisserial infection, unless the benefits of treatment outweigh the risks of contracting the infection. 52 Vaccination against N meningitidis serotypes A, C, Y, and W135 and meningococcus type B should be administered at least 2 weeks prior to initiation of eculizumab. If eculizumab treatment needs to be initiated immediately in a critically ill patient, prophylactic antibiotics should be given at the start of therapy and maintained for a minimum of 2 weeks 53 or as specified in individual country guidelines.
Management should also include supportive measures aimed at managing the risks and consequences of aHUS, such as hypertension, anemia, thrombocytopenia, acute renal failure, and infections, particularly in patients not receiving specific targeted treatment (eg, eculizumab). Hypertension is common in patients presenting with aHUS and should be managed with appropriate medications (angiotensin converting enzyme inhibitors or angiotensin receptor blockers), and red blood cell transfusion may be considered for patients with anemia, noting that platelet infusions are contraindicated unless the patient is bleeding or at high risk of hemorrhage (ie, at-risk surgical procedure) or severely thrombocytopenic (platelet count < 30,000/ mm 3 ). Because of the risk of relapse triggered by infections, physicians should be vigilant for signs of infection, initiating appropriate treatment where necessary. 1, 3 Recommendations for Standard of Care for Patients With aHUS in the ICU Using published recommendations 1 and expert opinions of our author group, recommendations for the standard of care for adult patients with aHUS in the ICU are outlined in Table 3 .
Outcomes of Critically Ill Patients With aHUS
Data regarding the outcomes of adult patients with aHUS are sparse because of the rarity of the disorder, and data relating to the treatment of such patients in the ICU are rarer still. However, existing studies agree that the prognosis of patients with aHUS is poor, with approximately 50% of patients requiring dialysis, suffering permanent kidney damage, or dying within 1 year of first occurrence despite plasma therapy. 4, 10, 54 In an Italian cohort, mortality after the first episode was 2% in adults; this was markedly lower than the 12% mortality rate reported in children in the same study. Furthermore, 32% of survivors never recovered renal function. 10 Despite plasma therapy, at 3 to 5 years after onset, 67% of adults with aHUS had either died or reached end-stage renal failure. 10 Kidney transplantation, although cited as a treatment option for aHUS, was, in fact, rarely considered because of an overall risk of recurrence after transplantation of 50%, with a high risk of graft rejection (up to 100%) in those with recurrence. 3 The risk of posttransplant recurrence varies according to the genetic mutation present and ranges from 0% to 30% in patients with membrane cofactor protein mutation, 40% to 70% with C3 mutation, 45% to 80% with complement factor I mutation, 75% to 90% with complement factor H mutation, and up to 100% with complement factor B mutation. 3, 10, 17, 55 Because of the high risk of graft rejection, living-donor transplantation is not recommended, particularly from living relations because of the 4. Careful ICU monitoring should be offered because organ dysfunction may appear or worsen until remission.
5. Because of the increased risk of Neisseria meningitidis infection with eculizumab treatment, patients should be vaccinated against serotypes A, C, Y, and W135 and subtype B 2 weeks before eculizumab is initiated; unvaccinated individuals should receive prophylactic antibiotics on eculizumab initiation until at least 2 weeks after N meningitidis vaccination (please refer to country-specific guidelines).
increased risk of the donor subsequently developing aHUS. 3 Since the approval of eculizumab, outcomes of patients with aHUS have improved significantly, causing a paradigm shift in the management of these patients. 19, 49 Notably, 80% of patients on dialysis at baseline could discontinue dialysis with eculizumab. 21, 47 A 2-year extension of a phase II study with eculizumab found that hematologic normalization was achieved by 13 of 17 patients after 26 weeks and by 15 patients at both years 1 and 2. In a retrospective study of 19 cases of aHUS in adults, all with acute kidney injury, nine had normal kidney function after 3 months' treatment with eculizumab. 56 
Conclusions
To our knowledge, this review is the first of its kind to outline the standard of care in critically ill adult patients with aHUS in the ICU. aHUS is defined by thrombocytopenia, nonimmune hemolytic anemia, and acute kidney injury, and often presents with associated organ dysfunction. Although TTP is fairly well recognized by critical care specialists, aHUS remains a diagnostic challenge because of the rarity of the disease. Because there are no specific tests, and aHUS is diagnosed by exclusion, diagnosis should be oriented toward aHUS if disseminated intravascular coagulation is ruled out, STEC test is negative, and plasma activity of ADAMTS13 is > 10%. For optimal patient outcomes, early recognition and appropriate treatment are critical to reduce the risk of irreversible organ damage or death. This review suggests initiating plasma therapy within 4 to 8 h of TMA diagnosis and switching to eculizumab treatment as early as possible after a confirmed aHUS diagnosis (ADAMTS13 > 10% and a negative STEC test).
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